Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Combined With Temozolomide in Postoperative Glioblastoma
ChiCTR-OPC-17010963Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thalidomide and temozolomide in glioblastoma (GBM), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: 1-year overall survival. Planned start May 2017; status: not yet recruiting.
02
Drugs
thalidomidetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR-OPC-17010963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010963.